Neoadjuvant Therapy Clinical Trial
Official title:
A Phase Ⅱ Study of Pre-Operative Concurrent Chemoradiotherapy With Capecitabine Plus Irinotecan in Resectable Rectal Cancer.
This study is to evaluate the pathologic complete response rate to pre-operative concurrent chemoradiotherapy with capecitabine plus irinotecan in resectable rectal cancer
This study is an open-label, single center, nonrandomized phase II study. Daily fractions of
radiotherapy at 1.8 Gy to total of 45 Gy to tumor and draining lymph nodes and followed by a
coned-down boost of 5.4 Gy to the tumor were delivered concurrently with chemotherapy.
Chemotherapy starts at day 1 of radiotherapy. Capecitabine is administered orally at a dose
of 825 mg/m2 twice daily during weekdays (Monday to Friday) every week during radiotherapy.
Irinotecan 40 mg/m2 is given intravenously once a week (D 1, 8, 15, 22 & 29).
Six ± 2 weeks after completion of chemoradiotherapy, curative surgery is performed.
Post-operative chemotherapy with capecitabine will be given to all patients 3-6 weeks after
surgery. Capecitabine 1,250 mg/m2 twice daily on days 1-14 every 21 days will be
administered for 18 weeks.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05996484 -
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04520737 -
Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases
|
N/A | |
Recruiting |
NCT06138496 -
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
|
Phase 2 | |
Not yet recruiting |
NCT05983094 -
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
|
Phase 2 | |
Terminated |
NCT04440982 -
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04028375 -
Study of CT and MR in the Gastric Cancer
|
||
Active, not recruiting |
NCT03192735 -
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04588987 -
Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma
|
Phase 2 | |
Not yet recruiting |
NCT05993858 -
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
|
Phase 2 | |
Active, not recruiting |
NCT04666090 -
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04848454 -
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
|
Phase 2 | |
Recruiting |
NCT04062058 -
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT06124378 -
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06125223 -
PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
|
||
Not yet recruiting |
NCT06404736 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06404463 -
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05371197 -
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06212440 -
Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy
|
N/A | |
Completed |
NCT03178032 -
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
|
Phase 1 |